AP - Bayer AG halted worldwide sales Monday of its anti-bleeding drug Trasylol at the request of U.S. and foreign health officials pending further analysis of a Canadian study that suggests it's linked to a 50 percent higher risk of death than the other drugs in the clinical trial.
AP - A type of "super X-ray"showed promise in its first big test as a potentially cheaper, faster and painless way to find out whether certain people with signs of heart disease actually have it and need treatment. The scans might eliminate the need for some of the 1.3 million cardiac catheterizations done each year in the United States to check for clogged arteries, said Dr. Julie Miller of Johns Hopkins University.
AP - It's time to pooper-scoop your leftover medicine. Mixing cough syrup, Vicodin or Lipitor with cat litter is the new advice on getting rid of unused medications —preferably used cat litter.
AP - Here's another reason to get the kids to bed early: More sleep may lower their risk of becoming obese. Researchers have found that every additional hour per night a third-grader spends sleeping reduces the child's chances of being obese in sixth grade by 40 percent.
AP - "Arthur"and "Barney"are OK for toddler TV-watching. But not "Rugrats"and certainly not "Power Rangers,"reports a new study of early TV-watching and future attention problems.
AFP - A quarter of men and women in 63 countries were found to be obese in a massive study of more than 168,000 people, France's top medical research institute said Monday.
HealthDay - TUESDAY, Oct. 30 (HealthDay News) -- Among prostate cancerpatients undergoing a high-tech form of radiation therapy, exposure to ahigher amount of radiation over a shorter time span poses no added riskfor impaired sexual function, new research reveals.
HealthDay - MONDAY, Nov. 5 (HealthDay News) -- Taking over-the-counter painmedicines called non-steroidal anti-inflammatory drugs (NSAIDs) may reducethe risk of Parkinson's disease, according to a study by researchers atthe UCLA School of Public Health in Los Angeles.
Reuters - Drugmaker Novacea Inc ended a late-stage trial of its prostate cancer drug Asentar, after a treatment arm containing the drug showed a higher death rate compared with the standard care, driving shares down more than 69 percent to a lifetime low.
